Safety of panitumumab-IRDye800CW and cetuximab-IRDye800CW for fluorescence-guided surgical navigation in head and neck cancers.

MLA

Gao, Rebecca W., et al. “Safety of Panitumumab-IRDye800CW and Cetuximab-IRDye800CW for Fluorescence-Guided Surgical Navigation in Head and Neck Cancers.” Theranostics, vol. 8, no. 9, Mar. 2018, pp. 2488–95. EBSCOhost, https://doi.org/10.7150/thno.24487.

APA

Gao, R. W., Teraphongphom, N., de Boer, E., van den Berg, N. S., Divi, V., Kaplan, M. J., Oberhelman, N. J., Hong, S. S., Capes, E., Colevas, A. D., Warram, J. M., & Rosenthal, E. L. (2018). Safety of panitumumab-IRDye800CW and cetuximab-IRDye800CW for fluorescence-guided surgical navigation in head and neck cancers. Theranostics, 8(9), 2488–2495. https://doi.org/10.7150/thno.24487

Chicago

Gao, Rebecca W, Nutte Teraphongphom, Esther de Boer, Nynke S van den Berg, Vasu Divi, Michael J Kaplan, Nicholas J Oberhelman, et al. 2018. “Safety of Panitumumab-IRDye800CW and Cetuximab-IRDye800CW for Fluorescence-Guided Surgical Navigation in Head and Neck Cancers.” Theranostics 8 (9): 2488–95. doi:10.7150/thno.24487.